Longeveron (LGVN) Cash & Equivalents (2021 - 2026)

Longeveron's (LGVN) quarterly Cash & Equivalents came in at $15.8 million in Q1 2026, up 9.99% year-on-year from $14.3 million in Q1 2025, and up 238.08% quarter-over-quarter from $4.7 million in Q4 2025.

Longeveron (LGVN) Cash & Equivalents (2021 - 2026) Analysis & Trends

Longeveron's Cash & Equivalents history runs 6 years deep, the most recent figure standing at $15.8 million for Q1 2026.

  • On a quarterly basis, Cash & Equivalents rose 9.99% year-over-year to $15.8 million in Q1 2026; TTM through Mar 2026 was $15.8 million, a 9.99% increase from a year earlier, with the FY2025 full-year figure at $4.7 million, down 75.76% from the prior year.
  • Cash & Equivalents grew to $15.8 million in Q1 2026 per LGVN's latest filing, from $4.7 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $22.8 million in Q3 2024 and bottomed at $1.9 million in Q1 2023.
  • The 5-year median for Cash & Equivalents is $9.8 million (2025), against an average of $9.5 million.
  • Across the five-year window, Cash & Equivalents jumped 1058.01% in 2024 and tumbled 75.76% in 2025, its largest moves.
  • Year by year, Cash & Equivalents stood at $10.5 million in 2022, then tumbled by 52.88% to $4.9 million in 2023, then soared by 288.6% to $19.2 million in 2024, then tumbled by 75.76% to $4.7 million in 2025, then soared by 238.08% to $15.8 million in 2026.
  • Per Business Quant, the three latest LGVN Cash & Equivalents figures stand at $15.8 million (Q1 2026), $4.7 million (Q4 2025), and $9.2 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Equiv. (Qtr)
1 Oculis Holding AG 67,042.03 Bn 67,041.74 Bn - 82.45 Mn
2 Nanobiotix 1,908.00 Bn 1,907.94 Bn - 61.40 Mn
3 Akari Therapeutics 959.56 Bn 959.56 Bn - 2.83 Mn
4 BeOne Medicines 472.89 Bn 468.10 Bn 1.35 Bn 4.79 Bn
5 Vertex Pharmaceuticals 122.12 Bn 114.87 Bn 2.59 Bn 5.49 Bn
6 Regeneron Pharmaceuticals 70.04 Bn 61.29 Bn 3.31 Bn 2.96 Bn
7 Belite Bio 62.68 Bn 62.68 Bn - -
8 Argenx Se 55.90 Bn 50.72 Bn 1.41 Bn 3.58 Bn
9 Alnylam Pharmaceuticals 37.47 Bn 34.46 Bn 959.66 Mn 1.71 Bn
10 Longeveron 15.28 Bn 15.26 Bn 264,000.00 15.76 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 15.76 Mn
Dec 31, 2025 4.66 Mn
Sep 30, 2025 9.24 Mn
Jun 30, 2025 10.30 Mn
Mar 31, 2025 14.33 Mn
Dec 31, 2024 19.23 Mn
Sep 30, 2024 22.78 Mn
Jun 30, 2024 12.40 Mn
Mar 31, 2024 1.94 Mn
Dec 31, 2023 4.95 Mn
Sep 30, 2023 1.97 Mn
Jun 30, 2023 2.75 Mn
Mar 31, 2023 1.90 Mn
Dec 31, 2022 10.50 Mn
Dec 31, 2021 25.66 Mn